AIM ImmunoTech Inc (AIM)
0.262
+0.02
(+8.26%)
USD |
NYAM |
Nov 14, 16:00
0.247
-0.02
(-5.73%)
After-Hours: 18:16
AIM ImmunoTech Research and Development Expense (Quarterly): 1.145M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 1.145M |
| March 31, 2024 | 1.951M |
| December 31, 2023 | 3.20M |
| September 30, 2023 | 2.734M |
| June 30, 2023 | 2.953M |
| March 31, 2023 | 2.052M |
| December 31, 2022 | 2.107M |
| September 30, 2022 | 1.372M |
| June 30, 2022 | 2.475M |
| March 31, 2022 | 1.036M |
| December 31, 2021 | 2.923M |
| September 30, 2021 | 2.006M |
| June 30, 2021 | 1.317M |
| March 31, 2021 | 1.424M |
| December 31, 2020 | 2.275M |
| September 30, 2020 | 1.102M |
| June 30, 2020 | 1.463M |
| March 31, 2020 | 0.898M |
| December 31, 2019 | 1.437M |
| September 30, 2019 | 1.19M |
| June 30, 2019 | 1.096M |
| March 31, 2019 | 0.928M |
| December 31, 2018 | 0.987M |
| September 30, 2018 | 1.595M |
| June 30, 2018 | 1.341M |
| Date | Value |
|---|---|
| March 31, 2018 | 0.855M |
| December 31, 2017 | 0.814M |
| September 30, 2017 | 0.787M |
| June 30, 2017 | 1.106M |
| March 31, 2017 | 1.391M |
| December 31, 2016 | 1.863M |
| September 30, 2016 | 1.342M |
| June 30, 2016 | 0.90M |
| March 31, 2016 | 1.002M |
| December 31, 2015 | 0.957M |
| September 30, 2015 | 1.968M |
| June 30, 2015 | 2.439M |
| March 31, 2015 | 2.674M |
| December 31, 2014 | 2.438M |
| September 30, 2014 | 1.894M |
| June 30, 2014 | 2.33M |
| March 31, 2014 | 2.326M |
| December 31, 2013 | 1.533M |
| September 30, 2013 | 2.173M |
| June 30, 2013 | 2.318M |
| March 31, 2013 | 2.336M |
| December 31, 2012 | 3.75M |
| September 30, 2012 | 2.357M |
| June 30, 2012 | 1.736M |
| March 31, 2012 | 1.665M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.898M
Minimum
Mar 2020
3.20M
Maximum
Dec 2023
1.888M
Average
1.951M
Median
Mar 2024
Research and Development Expense (Quarterly) Benchmarks
| Perspective Therapeutics Inc | 9.275M |
| Protalix BioTherapeutics Inc | 2.961M |
| Electromed Inc | 0.176M |
| Xtant Medical Holdings Inc | 0.636M |
| Armata Pharmaceuticals Inc | 8.475M |